ResearcherActive in the last 2 years

Cohava Gelber

ORCID-verified (high confidence)As of 9 November 2026

Matched on ORCID iD 0000-0002-3894-5021; OpenAlex author ID A5039227324.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper

Papers 1

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Last author DOI 10.2174/0115680096260614231115192343 ↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Kelly Arias Cardenas · 1 shared paper, 2024
- Paper CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancrea… DOI 10.2174/0115680096260614231115192343 ↗
Yong-Jun Kwon · 1 shared paper, 2024
- Paper CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancrea… DOI 10.2174/0115680096260614231115192343 ↗
J. Michael Pierce · 1 shared paper, 2024
- Paper CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancrea… DOI 10.2174/0115680096260614231115192343 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.